# Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

> **NCT04471844** · NA · COMPLETED · sponsor: **NovoCure Ltd.** · enrollment: 981 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DEVICE:** Optune®

## Key facts

- **NCT ID:** NCT04471844
- **Lead sponsor:** NovoCure Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-08
- **Primary completion:** 2026-02-19
- **Final completion:** 2026-02-19
- **Target enrollment:** 981 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04471844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04471844, "Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04471844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*